An Interaction Study of LY3200882 in Healthy Participants



Status:Completed
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 65
Updated:3/10/2019
Start Date:January 8, 2019
End Date:February 23, 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Effects of CYP3A4 Inhibition by Itraconazole on the Pharmacokinetics of LY3200882 in Healthy Subjects

The main purpose of this study is to evaluate the effect of itraconazole on the amount of
LY3200882 in the blood stream and how long the body takes to get rid of LY3200882. The safety
and tolerability of LY3200882 when given with itraconazole will be evaluated. The study is
expected to last up to 19 days from the first dose to follow-up (inclusive). Screening will
occur up to 28 days prior to enrollment.


Inclusion Criteria:

- Healthy males or postmenopausal females, as determined by medical history and physical
examination

Exclusion Criteria:

- Have a history or presence of cardiovascular, respiratory, hepatic, renal,
gastrointestinal, endocrine, hematological, or neurological disorders capable of
significantly altering the absorption, metabolism, or elimination of drugs; of
constituting a risk when taking the study medication; or of interfering with the
interpretation of data

- Have used or intend to use over-the-counter or prescription medication including
herbal medications within 14 days prior to dosing and during the study (with the
exception of vitamins and occasional acetaminophen or ibuprofen, which will be
permitted at the discretion of the investigator). Drugs that are known substrates,
inducers, or inhibitors of CYP3A4 are specifically excluded within 30 days of dosing
and throughout the study
We found this trial at
1
site
Covance Clinical Research Inc
Daytona Beach, Florida 32117
Principal Investigator: Lawrence A Galitz
Phone: 386-257-5717
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials